This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
Development PipelineSGN-CD228A
an investigational antibody–drug conjugate directed to CD228
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Clinical Trials
SGN228A-001: Advanced solid tumors
-
Phase 1
-
Phase 2
-
Phase 3
Program Resources

High-level synopsis of SGN-CD228A and ongoing clinical trials

Detailed information about SGN–CD228A clinical trials
Related Links